CoChat

Methylphenidate Exerts Dose-Dependent Effects on Glutamate Receptors and Behaviors

Open access
Cheng, Jia, Xiong, Zhe, Duffney, Lara J., Wei, Jing, Liu, Aiyi, Liu, Sihang, Chen, Guo-Jun, Yan, Zhen · 2014 · Biological Psychiatry
Cited by 75

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background Methylphenidate (MPH), a psychostimulant drug for the treatment of attention-deficit hyperactivity disorder (ADHD), produces the effects of increasing alertness and improving attention, while its misuse has been associated with an increased risk of aggression and psychosis. In this study, we sought to determine the molecular mechanism underlying the complex actions of MPH. Methods Adolescent (4-week-old) rats were given one injection of MPH at different doses. The impact of MPH on glutamatergic signaling in pyramidal neurons of prefrontal cortex (PFC) was measured. MPH-induced behavioral changes were also examined in parallel. Results We found that administration of low-dose (0.5 mg/kg) MPH selectively potentiated NMDAR-mediated excitatory synaptic currents (EPSCs) via adrenergic receptor activation, while the high-dose (10 mg/kg) MPH suppressed both NMDAR- and AMPAR-EPSCs. The dual effects of MPH on EPSCs were associated with bi-directional changes in the surface level of glutamate receptor subunits. Behavioral tests also indicated that low-dose MPH facilitated the PFC-mediated temporal order recognition memory (TORM) and attention, while animals injected with high-dose MPH exhibited significantly elevated locomotive activity. Inhibiting the function of SNAP-25, a key SNARE proteins involved in NMDAR exocytosis, blocked the increase of NMDAR-EPSC by low-dose MPH. In animals exposed to repeated stress, administration of low-dose MPH effectively restored NMDAR function and TORM via a mechanism dependent on SNAP-25. Conclusions Our results have provided a potential mechanism underlying the cognitive enhancing effects of low-dose MPH, as well as the psychosis-inducing effects of high-dose MPH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopsych.2014.04.003

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 40

  1. Biederman, 2005, Attention-deficit/hyperactivity disorder: A selective overview, Biol Psychiatry, 57, 1215, 10.1016/j.biopsych.2004.10.020 · DOI · Paper page
  2. Smith, 2011, Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals, Psychol Bull, 137, 717, 10.1037/a0023825 · DOI · Paper page
  3. Klein-Schwartz, 2002, Abuse and toxicity of methylphenidate, Curr Opin Pediatr, 14, 219, 10.1097/00008480-200204000-00013 · DOI · Paper page
  4. Gerasimov, 2000, Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study, J Pharmacol Exp Ther, 295, 51, 10.1016/S0022-3565(24)38868-8 · DOI · Paper page
  5. Wiley, 2009, Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate, Neuropsychopharmacology, 34, 1339, 10.1038/npp.2008.188 · DOI · Paper page
  6. Warren, 2011, Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood, J Neurosci, 31, 10347, 10.1523/JNEUROSCI.1470-11.2011 · DOI · Paper page
  7. Spencer, 2006, PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate, Am J Psychiatry, 163, 387, 10.1176/appi.ajp.163.3.387 · DOI · Paper page
  8. Arnsten, 2006, Fundamentals of attention-deficit/hyperactivity disorder: Circuits and pathways, J Clin Psychiatry, 67, 7
  9. Fernández, 2009, Complexity analysis of spontaneous brain activity in attention-deficit/hyperactivity disorder: Diagnostic implications, Biol Psychiatry, 65, 571, 10.1016/j.biopsych.2008.10.046 · DOI
  10. Lisman, 1998, A role for NMDA-receptor channels in working memory, Nat Neurosci, 1, 273, 10.1038/1086 · DOI · Paper page
  11. Kantrowitz, 2012, Glutamatergic transmission in schizophrenia: From basic research to clinical practice, Curr Opin Psychiatry, 25, 96, 10.1097/YCO.0b013e32835035b2 · DOI · Paper page
  12. Spear, 2000, The adolescent brain and age-related behavioral manifestations, Neurosci Biobehav Rev, 24, 417, 10.1016/S0149-7634(00)00014-2 · DOI · Paper page
  13. Yuen, 2011, Mechanisms for acute stress-induced enhancement of glutamatergic transmission and working memory, Mol Psychiatry, 16, 156, 10.1038/mp.2010.50 · DOI · Paper page
  14. Lou, 2012, Reduced release probability prevents vesicle depletion and transmission failure at dynamin mutant synapses, Proc Natl Acad Sci U S A, 109, 515, 10.1073/pnas.1121626109 · DOI · Paper page
  15. Wei, 2013, Estrogen protects against the detrimental effects of repeated stress on glutamatergic transmission and cognition [published online ahead of print Jul 9], Mol Psychiatry
  16. Manabe, 1993, Modulation of synaptic transmission and long-term potentiation: Effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus, J Neurophysiol, 70, 1451, 10.1152/jn.1993.70.4.1451 · DOI · Paper page
  17. Yang, 2006, Acute and chronic methylphenidate dose-response assessment on three adolescent male rat strains, Brain Res Bull, 71, 301, 10.1016/j.brainresbull.2006.09.019 · DOI
  18. Hargreaves, 1995, MK801-induced hyperactivity: Duration of effects in rats, Pharmacol Biochem Behav, 51, 13, 10.1016/0091-3057(94)00321-9 · DOI
  19. Barbaccia, 1986, Maprotiline: An antidepressant with an unusual pharmacological profile, J Pharmacol Exp Ther, 236, 307, 10.1016/S0022-3565(25)38881-6 · DOI · Paper page
  20. Andersen, 1989, The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action, Eur J Pharmacol, 166, 493, 10.1016/0014-2999(89)90363-4 · DOI · Paper page
  21. Cambridge, 1977, Prazosin, a selective antagonist of post-synaptic alpha-adrenoceptors, Br J Pharmacol, 59, 514
  22. Hamano, 2007, The alpha2-adrenergic receptor antagonist yohimbine improves endotoxin-induced inhibition of gastrointestinal motility in mice, Br J Anaesth, 98, 484, 10.1093/bja/aem011 · DOI
  23. Alburges, 1992, D1-receptor antagonists: Comparison of [3H]SCH39166 to [3H]SCH23390, J Chem Neuroanat, 5, 357, 10.1016/0891-0618(92)90051-Q · DOI
  24. Anderson, 2006, Administration of the D2 dopamine receptor antagonist sulpiride into the shell, but not the core, of the nucleus accumbens attenuates cocaine priming-induced reinstatement of drug seeking, Neuropsychopharmacology, 31, 1452, 10.1038/sj.npp.1300922 · DOI
  25. Jahn, 2006, SNAREs—engines for membrane fusion, Nat Rev Mol Cell Biol, 7, 631, 10.1038/nrm2002 · DOI · Paper page
  26. Cheng, 2013, SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors, J Physiol, 591, 3935, 10.1113/jphysiol.2013.255075 · DOI · Paper page
  27. Aarts, 2002, Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions, Science, 298, 846, 10.1126/science.1072873 · DOI · Paper page
  28. Jahn, 2012, Molecular machines governing exocytosis of synaptic vesicles, Nature, 490, 201, 10.1038/nature11320 · DOI · Paper page
  29. Lavaur, 2009, The membrane cytoskeletal protein adducin is phosphorylated by protein kinase C in D1 neurons of the nucleus accumbens and dorsal striatum following cocaine administration, J Neurochem, 111, 1129, 10.1111/j.1471-4159.2009.06405.x · DOI
  30. Urban, 2013, Treatment with a clinically-relevant dose of methylphenidate alters NMDA receptor composition and synaptic plasticity in the juvenile rat prefrontal cortex, Neurobiol Learn Mem, 101, 65, 10.1016/j.nlm.2013.01.004 · DOI · Paper page
  31. Steinpreis, 1996, The behavioral and neurochemical effects of phencyclidine in humans and animals: Some implications for modeling psychosis, Behav Brain Res, 74, 45, 10.1016/0166-4328(95)00162-X · DOI · Paper page
  32. Eshleman, 1999, Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type, J Pharmacol Exp Ther, 289, 877, 10.1016/S0022-3565(24)38214-X · DOI · Paper page
  33. Berridge, 2012, Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic α1- and α2-receptors, Biol Psychiatry, 71, 467, 10.1016/j.biopsych.2011.07.022 · DOI · Paper page
  34. Schwab, 2001, Calcium-dependent translocation of synaptotagmin to the plasma membrane in the dendrites of developing neurones, Mol Brain Res, 96, 1, 10.1016/S0169-328X(01)00244-3 · DOI
  35. Thompson, 1998, Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia, Biol Psychiatry, 43, 239, 10.1016/S0006-3223(97)00204-7 · DOI
  36. Barr, 2000, Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder, Mol Psychiatry, 5, 405, 10.1038/sj.mp.4000733 · DOI · Paper page
  37. Etain, 2010, A SNAP25 promoter variant is associated with early-onset bipolar disorder and a high expression level in brain, Mol Psychiatry, 15, 748, 10.1038/mp.2008.148 · DOI
  38. Wilson, 2000, Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder, Neurosci Biobehav Rev, 24, 51, 10.1016/S0149-7634(99)00064-0 · DOI
  39. Zehle, 2007, Methylphenidate treatment recovers stress-induced elevated dendritic spine densities in the rodent dorsal anterior cingulate cortex, Dev Neurobiol, 67, 1891, 10.1002/dneu.20543 · DOI · Paper page
  40. Wanchoo, 2009, Descending glutamatergic pathways of PFC are involved in acute and chronic action of methylphenidate, Brain Res, 1301, 68, 10.1016/j.brainres.2009.08.095 · DOI · Paper page

Cited by

See all 75

Metadata

Authors
Cheng, J., Xiong, Z., Duffney, L. J., Wei, J., Liu, A., Liu, S., Chen, G.-J., & Yan, Z.
Venue
Biological Psychiatry
Publisher
Elsevier BV
Published
2014-12
Volume
76
Issue
12
Pages
953-962
ISSN
0006-3223 (ISSN-L)
OpenAlex
W2012090610
Cited by
75
References
21
FWCI
3.35
Type
journal article
Language
en
Open access
bronze
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • National Institutes of Health (DA037618, MH085774, MH101690)
  • National Natural Science Foundation of China (81220108010, 81171197)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.